MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Fatigue in Parkinson’s disease and its relation with disease duration and treatment

D. Nassif, J. Pereira (Rio de Janeiro, Brazil)

Meeting: 2019 International Congress

Abstract Number: 1606

Keywords: Non-motor Scales, Parkinsonism

Session Information

Date: Wednesday, September 25, 2019

Session Title: Non-Motor Symptoms

Session Time: 1:15pm-2:45pm

Location: Agora 3 West, Level 3

Objective: Identify the presence of fatigue in a population of PD patients, establishing its association with disease duration and treatment.

Background: Fatigue is one of the most common and most disabling symptoms among PD patients and has a significant impact on their quality of life [1,2,3].

Method: This was an observational and cross-sectional study conducted in a movement disorder center in Pedro Ernesto University Hospital, Rio de Janeiro, Brazil. This study randomly recruited outpatients aged between 50 and 85 years-old with a confirmed diagnosis of idiopathic PD. Exclusion criteria included the following: dementia, any clinical condition related to fatigue, Hoehn & Yahr scale ≥ 4, medications associated with fatigue, including hypnotics, beta-blockers, benzodiazepines, muscle relaxants and anti-histamines, depressive symptoms, defined as scores > 19 on Beck Depression Inventory-II, excessive daytime sleepiness, defined as scores > 10 on Epworth Sleepiness Scale and apathy, defined as scores >14 on Apathy Scale. Patients were submitted to Fatigue Severity Scale (FSS) and those with score > 4 were considered to be fatigued. Disease duration and levodopa equivalent dose were assessed in all patients.

Results: A total of 237 PD patients were screened and according to exclusion criteria 184 patients were excluded, remaining 53 (22,36%) patients. All 53 patients completed the FSS and of these, 21 (39,62%) reported distressing fatigue (FSS > 4), with FSS score 5,26±0,87 compared to 2,31±1,02 (p<0,00) in non-fatigued patients. Comparisons between patients with fatigue vs those without fatigue showed that patients had the same age (64,75±7,23 vs 65,71±8,72, p<0,67), disease duration (7,25±3,64 vs 7,76±4,82, p<0,67), Hoehn & Yahr scale (2,39±0,38 vs 2,45±0,41, p<0,59) and levodopa equivalent dose (711,06±353,66 vs 719,61 ±389,24, p<0,94) (table 1).

Conclusion: Fatigue is an independent PD symptom, existing without the presence of confounding factors. It is was not associated with disease duration and levodopa equivalent dose,

Table 1.-1

References: Nassif DV, Pereira JS. Fatigue in Parkinson’s disease: concepts and clinical approach. Psychogeriatrics 2018;18:143–50. Friedman J, Friedman H. Fatigue in Parkinson’s disease. Neurology 1993;43:2016-2018. Friedman JH, Beck JC, Chou KL, et al. Fatigue in Parkinson’s disease: report from a mutidisciplinary symposium. NPJ Parkinsons Dis 2016;2

To cite this abstract in AMA style:

D. Nassif, J. Pereira. Fatigue in Parkinson’s disease and its relation with disease duration and treatment [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/fatigue-in-parkinsons-disease-and-its-relation-with-disease-duration-and-treatment/. Accessed May 17, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/fatigue-in-parkinsons-disease-and-its-relation-with-disease-duration-and-treatment/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley